Tech Company Financing Transactions
Senda Biosciences Funding Round
On 6/14/2021, Senda Biosciences raised $55 million in Series B funding from Alexandria Venture Investments, Flagship Pioneering and Longevity Fund.
Transaction Overview
Company Name
Announced On
6/14/2021
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the development of the company's platform and its therapeutic programs into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20 Acorn Park Dr. 300
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Senda harnesses the power of the interconnected, multi-species ecosystem within us to transform the way we treat and prevent disease. Senda Biosciences is the final iteration of several Flagship Pioneering efforts in intersystems biology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guillaume Pfefer
Chief Scientific Officer
Scott Plevy
VP - Bus. Development
John Casey
VP - Bus. Development
Nick Srikanth
VP - Human Resources
Paul Froisland
Browse more venture capital transactions:
Prev: 6/14/2021: RudderStack venture capital transaction
Next: 6/14/2021: Popmenu venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs